New diabetes drug MK-1403 enters early human safety trials

NCT ID NCT07242469

First seen Nov 21, 2025 · Last updated May 08, 2026 · Updated 19 times

Summary

This early-stage study tests a new medicine called MK-1403 in people with type 2 diabetes. The main goals are to check if it is safe and well-tolerated, and to see how the body processes it. Researchers will also measure if it lowers a marker of inflammation (hsCRP) in the blood. About 52 adults with type 2 diabetes will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advanced Pharma CR, LLC ( Site 0003)

    RECRUITING

    Miami, Florida, 33147, United States

    Contact Phone: •••-•••-••••

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)

    RECRUITING

    Springfield, Missouri, 65802, United States

    Contact Phone: •••-•••-••••

  • ProSciento Inc. ( Site 0001)

    RECRUITING

    Chula Vista, California, 91911, United States

    Contact Phone: •••-•••-••••

  • QPS-MRA, LLC ( Site 0004)

    RECRUITING

    Miami, Florida, 33143, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.